ATE309331T1 - Transplant-akzeptanz induzierende zellen monocytären ursprungs, sowie deren herstellung und verwendung - Google Patents

Transplant-akzeptanz induzierende zellen monocytären ursprungs, sowie deren herstellung und verwendung

Info

Publication number
ATE309331T1
ATE309331T1 AT03763823T AT03763823T ATE309331T1 AT E309331 T1 ATE309331 T1 AT E309331T1 AT 03763823 T AT03763823 T AT 03763823T AT 03763823 T AT03763823 T AT 03763823T AT E309331 T1 ATE309331 T1 AT E309331T1
Authority
AT
Austria
Prior art keywords
inducing cells
production
transplant
transplant acceptance
monocytic origin
Prior art date
Application number
AT03763823T
Other languages
German (de)
English (en)
Inventor
Bernd Karl Friedrich Kremer
Fred Faendrich
Maren Ruhnke
Original Assignee
Blasticon Biotech Forschung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blasticon Biotech Forschung filed Critical Blasticon Biotech Forschung
Application granted granted Critical
Publication of ATE309331T1 publication Critical patent/ATE309331T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/17—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT03763823T 2002-07-12 2003-07-11 Transplant-akzeptanz induzierende zellen monocytären ursprungs, sowie deren herstellung und verwendung ATE309331T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10231655A DE10231655A1 (de) 2002-07-12 2002-07-12 Transplantat-Akzeptanz induzierende Zellen monozytären Ursprungs, sowie deren Herstellung und Verwendung
PCT/EP2003/007551 WO2004007701A1 (en) 2002-07-12 2003-07-11 Transplant acceptance inducing cells of monocytic origin and their preparation and use

Publications (1)

Publication Number Publication Date
ATE309331T1 true ATE309331T1 (de) 2005-11-15

Family

ID=30009939

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03763823T ATE309331T1 (de) 2002-07-12 2003-07-11 Transplant-akzeptanz induzierende zellen monocytären ursprungs, sowie deren herstellung und verwendung
AT05009317T ATE390480T1 (de) 2002-07-12 2003-07-11 Transplant-akzeptanz induzierende zellen monocytären ursprungs, sowie deren herstellung und verwendung

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT05009317T ATE390480T1 (de) 2002-07-12 2003-07-11 Transplant-akzeptanz induzierende zellen monocytären ursprungs, sowie deren herstellung und verwendung

Country Status (18)

Country Link
US (1) US20060286670A1 (https=)
EP (2) EP1492869B9 (https=)
JP (1) JP2005532803A (https=)
CN (1) CN100523176C (https=)
AT (2) ATE309331T1 (https=)
AU (1) AU2003250939B2 (https=)
BR (1) BR0312693A (https=)
CA (1) CA2492383A1 (https=)
DE (3) DE10231655A1 (https=)
DK (2) DK1557462T3 (https=)
ES (3) ES2304647T3 (https=)
IL (3) IL166021A0 (https=)
NO (1) NO20050719L (https=)
PT (2) PT1557462E (https=)
RU (1) RU2370535C2 (https=)
SI (3) SI1557462T1 (https=)
WO (1) WO2004007701A1 (https=)
ZA (2) ZA200501054B (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10362002B4 (de) 2003-06-23 2006-10-12 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Adulte pluripotente Stammzellen
KR20060040671A (ko) * 2003-07-11 2006-05-10 블라스티콘 바이오테크놀로지셰 포르슝 게엠베하 단구성 기원의 자기 유래 자가 관용성 유도 세포 및약제학적 제제에 있어서의 이의 용도
EP1928479B1 (en) * 2005-08-24 2016-06-08 Yeda Research And Development Co., Ltd. Universal donor-derived tolerogenic cells for inducing non-syngeneic transplantation tolerance
RU2446826C2 (ru) 2005-10-14 2012-04-10 Фукуока Юниверсити Агенты для подавления повреждения трансплантированных островков после трансплантации островков
AR058135A1 (es) 2005-10-21 2008-01-23 Chugai Pharmaceutical Co Ltd Agentes para el tratamiento de cardiopatias
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
EP2025346B1 (en) 2006-04-07 2016-08-10 Osaka University Muscle regeneration promoter
WO2008090901A1 (ja) * 2007-01-23 2008-07-31 Shinshu University 慢性拒絶反応抑制剤
TWI528973B (zh) 2008-06-05 2016-04-11 Chugai Pharmaceutical Co Ltd Nerve infiltration inhibitor
EP2365823B1 (en) * 2008-10-30 2016-11-30 Yeda Research And Development Company Ltd. Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
JP5436905B2 (ja) * 2009-03-26 2014-03-05 テルモ株式会社 シート状細胞培養物の製造方法
JP5667357B2 (ja) * 2009-11-30 2015-02-12 テルモ株式会社 シート状細胞培養物の製造方法
CN101812428A (zh) * 2010-04-26 2010-08-25 西北农林科技大学 一种乳腺上皮细胞的组织块种植方法
JP6051049B2 (ja) 2010-05-28 2016-12-21 中外製薬株式会社 抗腫瘍ｔ細胞応答増強剤
DE102011004335A1 (de) 2011-02-17 2012-08-23 Thomas Grammel Verfahren zur Herstellung eines Vakzins
RU2508924C1 (ru) * 2013-02-21 2014-03-10 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" Способ профилактики и лечения отторжения почечного трансплантата
JP5727665B2 (ja) * 2014-12-11 2015-06-03 テルモ株式会社 シート状細胞培養物の製造方法
JP5893786B2 (ja) * 2015-04-02 2016-03-23 テルモ株式会社 シート状細胞培養物の製造方法
KR102769850B1 (ko) * 2015-07-03 2025-02-20 인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰 메디칼르 조절 t 세포를 수득하는 방법 및 이의 용도
JP6903866B2 (ja) * 2016-01-27 2021-07-14 国立大学法人 熊本大学 血液由来単球の増殖誘導方法
JP6140322B2 (ja) * 2016-02-24 2017-05-31 テルモ株式会社 シート状細胞培養物の製造方法
JP6490738B2 (ja) * 2017-04-28 2019-03-27 テルモ株式会社 シート状細胞培養物の製造方法
EP3620531A4 (en) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS
EP3698808B1 (en) 2017-10-20 2025-01-01 Hyogo College Of Medicine Anti-il-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
WO2019151418A1 (ja) 2018-01-31 2019-08-08 元一 加藤 Ｉｌ－６阻害剤を含有する喘息の治療剤
JP6657452B2 (ja) * 2019-02-27 2020-03-04 テルモ株式会社 シート状細胞培養物の製造方法
IL287220B2 (en) 2019-04-17 2026-03-01 Univ Hiroshima A therapeutic agent for urological cancer characterized by administering an IL-6 inhibitor in combination with a CCR2 inhibitor
JP7002497B2 (ja) * 2019-06-20 2022-01-20 テルモ株式会社 シート状細胞培養物の製造方法
JP6872051B2 (ja) * 2020-02-05 2021-05-19 テルモ株式会社 シート状細胞培養物の製造方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766920A (en) * 1982-08-11 1998-06-16 Cellcor, Inc. Ex vivo activation of immune cells
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
US9068164B1 (en) * 1995-02-02 2015-06-30 Tristem Trading (Cyprus) Limited Method of preparing an undifferentiated cell
US7410773B2 (en) * 1995-02-02 2008-08-12 Ghazi Jaswinder Dhoot Method of preparing an undifferentiated cell
US7112440B2 (en) * 1995-02-02 2006-09-26 Ghazi Jaswinder Dhoot Method of increasing the relative number of CD45 low cells in a cell population
GB9502022D0 (en) * 1995-02-02 1995-03-22 Abuljadayel Ilham M S A method for preparing lymphohaematopoietic progenitor cells
JP3926842B2 (ja) * 1995-03-08 2007-06-06 ザ・スクリプス・リサーチ・インステイチユート 抗原提示系およびｔ−細胞の活性化方法
WO1998053048A1 (en) * 1997-05-21 1998-11-26 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods and compositions for making dendritic cells from expanded populations of monocytes and for activating t cells
NL1017973C2 (nl) * 2000-05-10 2002-11-08 Tristem Trading Cyprus Ltd Inrichting.
DE60108661T2 (de) * 2000-11-14 2006-01-05 Université Libre de Bruxelles Herstellung und verwendung von dendritischen zellen
TWI288779B (en) * 2002-03-28 2007-10-21 Blasticon Biotech Forschung Dedifferentiated, programmable stem cells of monocytic origin, and their production and use

Also Published As

Publication number Publication date
IL166021A0 (en) 2006-01-15
EP1492869B1 (en) 2005-11-09
DE10231655A1 (de) 2004-02-26
NO20050719L (no) 2005-04-04
ES2310711T3 (es) 2009-01-16
ZA200601074B (en) 2007-11-28
SI1644484T1 (sl) 2009-02-28
IL172854A0 (en) 2006-06-11
DK1557462T3 (da) 2008-06-23
DE60320009D1 (de) 2008-05-08
RU2005103627A (ru) 2005-08-27
CN1681918A (zh) 2005-10-12
DK1492869T3 (da) 2006-03-06
EP1557462B1 (en) 2008-03-26
ZA200501054B (en) 2005-08-30
EP1492869B9 (en) 2006-05-24
DE60302231D1 (de) 2005-12-15
ES2252696T3 (es) 2006-05-16
PT1644484E (pt) 2008-10-21
SI1492869T1 (sl) 2006-04-30
DE60320009T2 (de) 2009-05-20
CA2492383A1 (en) 2004-01-22
JP2005532803A (ja) 2005-11-04
CN100523176C (zh) 2009-08-05
IL166021A (en) 2010-05-17
SI1557462T1 (sl) 2008-08-31
EP1557462A2 (en) 2005-07-27
PT1557462E (pt) 2008-06-18
ATE390480T1 (de) 2008-04-15
ES2304647T3 (es) 2008-10-16
DE60302231T2 (de) 2006-07-20
BR0312693A (pt) 2005-04-26
WO2004007701A1 (en) 2004-01-22
AU2003250939A1 (en) 2004-02-02
EP1492869A1 (en) 2005-01-05
RU2370535C2 (ru) 2009-10-20
EP1557462A3 (en) 2006-02-01
AU2003250939B2 (en) 2008-05-22
HK1071586A1 (en) 2005-07-22
US20060286670A1 (en) 2006-12-21

Similar Documents

Publication Publication Date Title
ATE390480T1 (de) Transplant-akzeptanz induzierende zellen monocytären ursprungs, sowie deren herstellung und verwendung
DE602006006200D1 (de) Antikörper gegen 25-hydroxyvitamin d
ATE393169T1 (de) Il-7-fusionsproteine mit antikörperportionen, deren herstellung und deren verwendung
MA30497B1 (fr) Anticorps et immunco-conjugues, et leurs utilisations.
DK1553975T3 (da) Optimerede Fc-varianter og fremgangsmåder til generering heraf.
BRPI0410031A (pt) variantes fc otimizadas e métodos para sua geração
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
ATE507839T1 (de) Kombinationstherapie
NO20074563L (no) Novel anti-plgf antibody
ATE395082T1 (de) Antikörper gegen krebsantigen tmeff2 und seine anwendungen
DE50208918D1 (de) 6-aminomorphinanderivate, herstellungsverfahren dafür und deren verwendung
ATE517340T1 (de) Sätze gegen kurze epitope gerichteter digitaler antikörper sowie diese verwendende verfahren
ATE525480T1 (de) Verwendung von a33-antigenen und jam-it
DE602004017326D1 (de) Tetrahydrocarbazolderivate und deren pharmazeutische verwendung
EP1513397A4 (en) Transgenic mammals capable of producing human antibodies
EE200500012A (et) Peptiid-pähine passiivne immunoteraapia ateroskleroosi raviks
BR0313135A (pt) Epìtopos de células t em eritropoietina
UA94211C2 (ru) Выделенное полностью человеческое моноклональное cd3 антитело
DK2335720T3 (da) Autolog T-cellevacciner mod multiple sclerose
DE602004024574D1 (de) Humane anti-idiotypische antikörperfragmente, die her-2/neu ähneln
ATE494307T1 (de) Neoplasma-spezifische antikörper und deren verwendungen
CY1112194T1 (el) Μεθοδοι για ρυθμιση φωτοτοξικοτητας
WO2005047456A3 (en) Anti-idiotype antibodies of the human monoclonal antibody sc-1, and their production and use
ATE382062T1 (de) Antikörper gegen allgegenwärtige mitochondriale kreatinkinase und dessen verwendung
CY1114962T1 (el) Ανοσοδιαμορφωση χρησιμοποιωντας πλακουντιακα βλαστικα κυτταρα

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1492869

Country of ref document: EP

REN Ceased due to non-payment of the annual fee